GEn1E Lifesciences is a clinical-stage AI platform company advancing therapies for rare, inflammatory and age-related diseases. Using our Platform we have developed a rich pipeline of novel therapies. Our lead compound is in development for therapeutic treatment of ARDS (Acute Respiratory Distress Syndrome) which is a devastating disease with no FDA approved treatment and $100K+ cost of care per patient. It is also the leading cause of death in serious COVID-19 patients. GEn1E's team is composed of professionals with decades of experience in drug development, machine learning, and entrepreneurship at global companies and institutions such as Roche, Abbott, UCSF, and Stanford University. GEn1E has raised seed funding from Y-Combinator, Stanford-StartX, Khosla Ventures, Vituity (3500+ Physician network), and notable angel investors. GEn1E Lifesciences is based in Palo Alto with a laboratory in Mountain View, CA.Something looks off?